The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.
url:  https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program

This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.

Stage of discovery:

• Preclinical pharmacokinetics (PK) and pharmacodynamics (PD) (primarily in wild-type animals to inform dose selection for in vivo efficacy studies), as well as preliminary rodent tolerability studies.
• In vivo efficacy or proof-of-concept studies in animal models of disease or aging, with a focus on measures of direct and indirect markers of target engagement and downstream pharmacologic effects.

Therapeutic modalities: Includes small molecules, biologics, gene therapies, antisense oligonucleotides, and stem cells.